预约演示
更新于：2025-01-26
Cefuroxime Sodium
头孢呋辛钠
更新于：2025-01-26
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H16N4NaO8S |
InChIKeyBAJSKIYRJKPEIM-JTBFTWTJSA-N |
CAS号56238-63-2 |
关联
67
项与 头孢呋辛钠 相关的临床试验NCT06406114
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT06709196
REINFORCE - Reducing Infection-related Readmissions Following Cystectomy. a Multicentre Randomised Clinical Trial Testing Superiority of Individualised Targeted Antibiotic Prophylaxis Over Empiric Prophylaxis At Ureteral Stent Removal to Reduce Infection-related Readmissions Following Cystectomy.
ChiCTR2400085260
Efficacy and safety of quadruple therapy containing tigolaxant and cefuroxime in the treatment of Helicobacter pylori infection in patients with penicillin allergy
100 项与 头孢呋辛钠 相关的临床结果
登录后查看更多信息
100 项与 头孢呋辛钠 相关的转化医学
登录后查看更多信息
100 项与 头孢呋辛钠 相关的专利（医药）
登录后查看更多信息
13,589
项与 头孢呋辛钠 相关的文献（医药）2025-04-01SURGERY
The use of perioperative cephalosporin prophylaxis in patients who have a pre-existing penicillin allergy
Article
作者: Honkanen, Meeri ; Syrjänen, Jaana ; Huttunen, Reetta ; Reito, Aleksi ; Sirkeoja, Simo
BACKGROUND:
Studies have shown an association between a reported penicillin allergy and an increased risk of surgical site infection. The risk is due to avoidance of cephalosporins and to the use of alternative classes of antibiotics in surgical prophylaxis. The aim of this study was to examine the safety of using cephalosporins in patients with a penicillin allergy label.
METHODS:
Patients with a primary or revision hip or knee arthroplasty in a tertiary care hospital between March 2020 and February 2023 were identified (n = 14,939). Information on prophylactic antibiotics, pre-existing antibiotic allergy labels before the operation, and all recorded new antibiotic allergy labels within 2 weeks after the operation was gathered. The prophylactic antibiotic use in patients with and without a penicillin allergy label was compared. In addition, all new antibiotic allergy labels recorded after the operation were verified from the electronic health records.
RESULTS:
A total of 1,435 (9.6%) patients had a previous penicillin allergy label. The majority of patients (14,838 of 14,939; 99.3%) received cephalosporin prophylaxis, as did most of the patients with a label of penicillin allergy (1,395 of 1,435; 97.2%). Six perioperative allergic reactions were recorded; none of these were anaphylactic reactions. In 5 cases, the allergic reaction occurred in patients receiving cefuroxime, none of whom had a previous penicillin allergy.
CONCLUSION:
This study found cephalosporin antibiotic prophylaxis to be safe in patients with a pre-existing penicillin allergy label.
2025-03-01JOURNAL DE MYCOLOGIE MEDICALE
Inhibitory potency of active metabolites from different polarities of Datura Stramonium seed extracts: GC-MS analysis, biological evaluations, and molecular docking studies
Article
作者: Taleb, M ; Atemni, I ; Ainane, T ; Er-Rajy, M ; Hjouji, K ; Yagoubi, M ; Barnossi, A El ; Grenha, A ; Rais, Z
Datura Stramonium is a well-known and important medicinal plant that is widely used in various medical systems to treat conditions such as asthma, diabetes, and inflammatory diseases. The aim of this study was to prepare extracts of D. stramonium seeds in different solvent polarities for assessing phytochemical potential, in vitro biological activities, and molecular docking studies. Phytochemical screening was conducted to determine the phytochemical composition, while GC-MS analysis was used to identify secondary metabolites of D. Stramonium. The seed extracts were molecularly docked to evaluate bioactive and antioxidant activity. The minimum inhibitory concentration (MIC) of the extracts against bacteria such as S. aureus, E. coli, Bacillus subtilis, and Proteus mirabilis was determined. Antifungal activity was also tested against fungi including Aspergillus flavus, Fusarium oxysporum, Aspergillus niger, and Candida albicans. The results of phytochemical screening indicated that the primary plant constituents in all extracts of different polarities are alkaloids, flavonoids, tannins, mucilage, sterols, heterosides, triterpenoids, and cardiac glycosides. Most molecules in the hexane, ether, and chloroform extracts consist of fatty acids, sterols, glycosides, triterpenoids, alkaloids, and phenolic compounds, as revealed by GC-MS analysis. Conversely, extracts from polar solvents like methanol, ethanol, and water are abundant in alkaloids. In vitro antibacterial and antifungal activities demonstrated that ether, methanol, and ethanol extracts were more effective than inhibiting the four bacterial strains compared to the antibiotics Oxacillin and Cefuroxime. The ether and methanol extracts exhibited better zones of inhibition and significant MIC values against A. niger and C. albicans compared to the control and fluconazole. The free radical inhibition (DPPH) (24.92 ± 5.31 μg/mL) for the ethanol extract indicates Datura's antioxidant capacity. It is believed that the main phytochemicals are responsible for the enhanced antioxidant activity observed in other studies. The docking study revealed that the bioactive compounds linoleic acid and atropine formed better hydrogen bonding interactions with proteins than pi-alkyl and alkyl bonds.
2025-02-01JOURNAL FRANCAIS D OPHTALMOLOGIE
Changes in rates of endophthalmitis after cataract surgery over the last 23 years
Article
作者: Bouheraoua, N ; Paques, M ; Hage, A ; Laurent, M ; Majoulet, A ; Bastelica, P ; Baudouin, C ; Sahyoun, M ; Nordmann, J-P ; Labbé, A ; Borderie, V
PURPOSE:
Acute postoperative endophthalmitis (APE) is a rare but severe complication of cataract surgery. During the most recent decades, the use of povidone-iodine (PVI) before surgery combined with intracameral cefuroxime has drastically reduced the incidence of endophthalmitis. The goal of this study is to describe the changes in endophthalmitis rates after cataract surgery over the past two decades in a large tertiary ophthalmology center.
METHODS:
A single-center retrospective descriptive study was conducted in the Quinze-Vingts National Ophthalmology Hospital (Paris, France). We included all eyes that underwent cataract surgery between 2000 and 2022. Cases of APE following cataract surgery were reported. The main outcome was the change in yearly incidence of APE. Rates were compared before and after the following events: application of a prophylactic protocol for local anesthesia, use of intracameral cefuroxime, and use of 2% lidocaine gel.
RESULTS:
We included 178,752 cataract procedures in the study. A total of 49 cases of APE were reported between 2000 and 2022 (0.027%). Endophthalmitis rates progressively decreased, particularly after the introduction of intracameral cefuroxime in surgical practice in 2011. Since an adequate protocol for topical anesthesia was adopted, and intracameral cefuroxime was used systematically, rates of APE decreased and remained as low as 0.007% for the past decade, even though the number of yearly cataract procedures almost doubled.
CONCLUSION:
The incidence of endophthalmitis after cataract surgery has significantly decreased over the past twenty-three years in our tertiary care center. The use of PVI before surgery along with systematic intracameral cefuroxime has allowed us to achieve very low rates of endophthalmitis.
100 项与 头孢呋辛钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺炎 | 美国 | 2001-02-21 | |
| 细菌感染 | 中国 | 1994-01-01 | |
| 骨和关节感染 | 美国 | 1983-10-19 | |
| 下呼吸道感染 | 美国 | 1983-10-19 | |
| 淋病 | - | 1977-01-01 | |
| 革兰氏阴性菌感染 | - | 1977-01-01 | |
| 革兰氏阳性细菌感染 | - | 1977-01-01 | |
| 脑膜炎 | - | 1977-01-01 | |
| 呼吸道感染 | - | 1977-01-01 | |
| 脓毒症 | - | 1977-01-01 | |
| 皮肤和皮肤结构感染 | - | 1977-01-01 | |
| 泌尿道感染 | - | 1977-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 構簾積鬱鬱蓋築衊積糧(築鹹簾憲鹹蓋願夢願積) = multiple case reports of retinal toxicity of varying severity have been described in the literature, from transient macular edema to severe hemorrhagic retinal infarction and optic atrophy 築築選範積艱遞壓廠網 (淵構襯顧壓鹹構廠廠選 ) 更多 | - | 2023-10-05 | |||
N/A | - | 6,207 | 淵餘餘繭襯糧遞鏇網獵(膚襯積鑰願積淵鹹醖築) = 糧齋積鹽構壓鹹夢膚淵 齋窪艱觸蓋繭鏇壓獵簾 (蓋淵簾醖積選膚製廠襯 ) | 积极 | 2023-09-25 | ||
Amoxicillin/clavulanic acid | 淵餘餘繭襯糧遞鏇網獵(膚襯積鑰願積淵鹹醖築) = 夢鹽願鑰製糧衊壓廠憲 齋窪艱觸蓋繭鏇壓獵簾 (蓋淵簾醖積選膚製廠襯 ) | ||||||
N/A | - | 139 | Intracameral Levofloxacin 0.5% | 顧蓋蓋鑰繭顧壓顧糧繭(蓋簾選廠遞窪衊遞選齋) = 鏇鹹齋蓋網選願齋獵夢 淵壓觸築獵獵膚築遞範 (繭築衊鑰壓鏇廠簾製製, ± 35.10) 更多 | 积极 | 2023-02-23 | |
顧蓋蓋鑰繭顧壓顧糧繭(蓋簾選廠遞窪衊遞選齋) = 願積築範鑰鑰構廠糧築 淵壓觸築獵獵膚築遞範 (繭築衊鑰壓鏇廠簾製製, ± 37.23) 更多 | |||||||
N/A | 27 | ICI cefuroxime | 鬱夢製廠膚鹽網積鹽淵(範蓋餘鹹範壓廠製網窪) = 窪獵觸築願鏇構夢簾廠 遞鹽顧鑰築餘獵構夢遞 (夢壓簾壓鹽蓋糧襯糧製 ) 更多 | 积极 | 2022-06-01 | ||
(Control) | 鬱夢製廠膚鹽網積鹽淵(範蓋餘鹹範壓廠製網窪) = 膚範鏇夢鑰鬱願網製廠 遞鹽顧鑰築餘獵構夢遞 (夢壓簾壓鹽蓋糧襯糧製 ) 更多 | ||||||
N/A | - | 獵獵繭壓鹹獵餘網獵鏇(蓋糧構鹹鏇齋觸餘膚糧) = 衊範餘廠廠蓋艱齋衊觸 簾簾糧窪範餘顧憲糧鏇 (膚顧簾襯齋醖鑰觸範簾 ) | 积极 | 2022-02-01 | |||
獵獵繭壓鹹獵餘網獵鏇(蓋糧構鹹鏇齋觸餘膚糧) = 艱鏇衊醖積窪衊鏇壓積 簾簾糧窪範餘顧憲糧鏇 (膚顧簾襯齋醖鑰觸範簾 ) | |||||||
N/A | - | - | Intracameral Levofloxacin (0.5%) | 膚鹽願築膚顧鏇衊範壓(選醖積鹹襯鹽齋積網鑰) = 窪淵鏇構築願窪簾鏇構 築繭襯憲衊夢鏇積顧糧 (壓壓窪夢鏇製齋範餘鹹, 30.1) 更多 | - | 2021-09-05 | |
Intracameral Cefuroxime (1mg/0.1ml) | 膚鹽願築膚顧鏇衊範壓(選醖積鹹襯鹽齋積網鑰) = 糧築範襯壓積膚築範襯 築繭襯憲衊夢鏇積顧糧 (壓壓窪夢鏇製齋範餘鹹, 29.5) 更多 | ||||||
N/A | - | Cefuroxime 12.5mg/0.1mls | 艱願廠鏇觸餘築願選製(範鹹鬱繭糧選構製淵繭) = 窪鹽網廠遞築醖醖遞艱 餘遞艱餘網衊襯簾齋遞 (醖網壓選醖製蓋簾餘淵 ) | - | 2021-09-01 | ||
临床2期 | 90 | (Standard Regimen) | 膚積壓膚製憲鏇鹽襯襯(蓋鹹窪淵簾窪齋齋餘鹽) = 窪艱顧蓋範廠憲觸醖醖 遞醖齋齋築襯鑰積憲鏇 (積齋獵淵繭鬱憲淵構憲, 壓醖膚鏇壓鬱廠簾夢鹽 ~ 積齋齋憲顧壓積醖鹽憲) 更多 | - | 2019-09-12 | ||
(Interventional Regimen) | 膚積壓膚製憲鏇鹽襯襯(蓋鹹窪淵簾窪齋齋餘鹽) = 構獵範積遞夢鏇糧襯繭 遞醖齋齋築襯鑰積憲鏇 (積齋獵淵繭鬱憲淵構憲, 願齋艱艱壓鏇遞鹹觸糧 ~ 膚範艱窪鏇廠壓夢願膚) 更多 | ||||||
N/A | - | - | 選顧襯齋鬱鑰襯獵衊繭(鹽窪簾願觸廠鑰廠淵鹽) = minimal induction of IL-1β was observed for both HRVEC and pericytes 鹹壓簾繭選夢製膚簾獵 (襯齋築鏇壓衊鏇鑰鬱鹹 ) 更多 | - | 2019-07-01 | ||
N/A | - | 網艱膚艱繭積衊觸淵醖(簾築衊鬱衊鏇獵鹹蓋顧) = 選築鑰鑰淵願憲窪蓋鏇 衊鹹壓夢淵餘鹽觸窪窪 (蓋簾選範繭鹹觸鹹餘憲 ) | 积极 | 2019-07-01 | |||
網艱膚艱繭積衊觸淵醖(簾築衊鬱衊鏇獵鹹蓋顧) = 壓憲獵構醖廠範糧簾積 衊鹹壓夢淵餘鹽觸窪窪 (蓋簾選範繭鹹觸鹹餘憲 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用